| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
ssK36 TFA targets the SET domain of protein lysine methyltransferase SETD2. This enzyme is responsible for the trimethylation of histone H3 at lysine 36 (H3K36me3) in humans, a key epigenetic mark associated with active transcription elongation, mRNA splicing, and DNA damage repair. As a supersubstrate peptide, it acts as a highly sensitive biochemical probe for the catalytic mechanism of SETD2. It is designed to have a dramatically enhanced methylation rate, enabling detailed kinetic studies.
|
|---|---|
| ln Vitro |
In non-cellular biochemical assays, ssK36 TFA can be methylated by SETD2 at a rate more than 100 times faster than the natural H3K36 substrate, making it an extremely sensitive and efficient tool for high-throughput screening and kinetic analyses. It is also used in peptide binding assays to characterize the interaction of SETD2 with its substrates. No activity in cellular or in vivo systems is reported.
|
| ln Vivo |
No in vivo activity data are available for ssK36 TFA. The peptide is specifically designed and utilized as an in vitro biochemical tool for enzyme characterization and high-throughput screening, not for use in living animals. As a peptide, it would be rapidly degraded in serum and is not suitable for in vivo pharmacokinetic or efficacy studies.
|
| Enzyme Assay |
For non-cellular assays, a standard SETD2 methyltransferase activity assay is used. The protocol involves: 50 uL reaction mixture in 96-well plates containing 25 mM Tris-HCl pH 8.0, 5 mM DTT, 10 mM MgCl2, 0.1% Tween 20, 5 uM recombinant SETD2, 1 uM ssK36 TFA, and 5 uM [3H]-SAM (S-adenosyl methionine). After incubation at 30degC for 60 min, the reaction is stopped with 10 uL of 5% TCA. The mixture is spotted onto P81 filter paper, washed, and counted in a scintillation counter. For inhibitor studies, the compound is pre-incubated with the enzyme.
|
| Cell Assay |
Not applicable. ssK36 TFA is a peptide exclusively used for non-cellular, in vitro enzymatic assays or binding studies. It is not intended for live cell treatment. For research use only.
|
| Animal Protocol |
No in vivo animal studies are performed with ssK36 TFA, as it is an in vitro biochemical tool.
|
| ADME/Pharmacokinetics |
As a research peptide, detailed pharmacokinetic data are not available. It is supplied as a lyophilized powder. Molecular formula: C79H127N29O18·xC2HF3O2, molecular weight: 1771.04 (free base). Purity: 99.34% by HPLC. Solubility: H2O (~1 mg/mL with sonication). Storage: powder at -20degC for 3 years or at -80degC for 2 years; in solution at -80degC for 6 months. The peptide should be stored in a sealed environment, away from moisture.
|
| Toxicity/Toxicokinetics |
No toxicity data are available for ssK36 TFA. As a research peptide, standard safety precautions for laboratory handling should be followed. This includes the use of PPE (gloves, lab coat) and working in a well-ventilated area. For research use only; not for human use. Waste disposal should follow local regulations for chemical and biological waste.
|
| References | |
| Additional Infomation |
Peptide sequence: Ala-Pro-Arg-Phe-Gly-Gly-Val-Lys-Arg-Pro-Asn-Arg-Tyr-Arg-Pro (APRFGGVKRPNRYRP). Purity: 99.34%. Amino acids 29-43 of H3K36 with modifications. Research areas: epigenetics, histone methyltransferase, cancer biology. For research use only.
|
| Molecular Formula |
C79H127N29O18.XC2HF3O2
|
|---|---|
| Molecular Weight |
1771.04 (free base)
|
| Related CAS # |
ssK36
|
| Sequence |
Ala-Pro-Arg-Phe-Gly-Gly-Val-Lys-Arg-Pro-Asn-Arg-Tyr-Arg-ProAPRFGGVKRPNRYRP
|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~1 mg/mL (with sonication)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
